Scientific InsightsWhite papers, conference posters and articles

Access scientific publications with rigorously developed data and expert analysis to support evaluation of equipment, assays and workflows, so you can confidently evaluate and advance your laboratory strategy. Featuring clear visuals and comprehensive insights, this content is published in peer-reviewed journals and presented in leading conferences.

Disease State

: Prognosis for Adverse Events in Suspected ACS Without MI, and Subgroups With or Without History of Incident and Previous MACE Using the Atellica IM High-Sensitivity Troponin I Assay
This analysis evaluated the association between initial hs‑cTnI concentrations and all‑cause mortality or MACE in emergency department patients with suspected ACS.
External Clinical Verification of the Atellica CI High-Sensitivity Troponin I Assay
This evaluation assessed the reproducibility and clinical concordance performance characteristics of the Atellica IM TnIH assay on the Atellica CI and Atellica IM Analyzers.
: Performance Evaluation of the EMIT II Plus Oxycodone, Buprenorphine, and 6-acetylmorphine Assays on the Atellica DT 250 System
The Emit II Plus Oxycodone, Buprenorphine, and 6-Acetylmorphine assays on the new Atellica DT 250 System provide suitable screening methods for urine specimens for both qualitative and semiquantitative analyses.
: INNOVANCE Antithrombin assay to manage fitusiran dosing
INNOVANCE Antithrombin fulfills requirements needed to support Qfitlia dose establishment and monitoring in individuals with hemophilia A or B.
ISTH poster from external collaborators: Diagnosis of von Willebrand Disease: comparison between conventional versus automated assays
Data presented in this poster demonstrate that INNOVANCE VWF Ac can be used in routine clinical practice to measure VWF activity.
Quantitative Determination of Apixaban
The INNOVANCE Anti-Xa assay in combination with INNOVANCE Apixaban Standards and Controls can be used for the quantitative measurement of apixaban in human-citrated plasma.
: Real World Assessment of the Impact of Infectious Disease Assays on Workflow Capabilities of Atellica IM Analyzer
This White Paper reviews real‑world Atellica IM instrument data assessing throughput and test mix considerations for immunoassay and ID testing.
Human immunodeficiency virus (HIV): Updates on testing support
This White Paper examines global strategies to expand HIV testing, including laboratory‑based antigen‑antibody testing on platforms such as ADVIA Centaur and Atellica IM Analyzers.
Evaluation of the Analytical Performance of the Total Antibodies to Hepatitis B Core Antigen Assay on the Atellica CI Analyzer
Precision and method comparison studies for the Atellica IM CHIV assay were evaluated using the Atellica CI Analyzer.
Comparison of high-throughput fully automated immunoanalyzers for detecting hepatitis B virus infection
This article compares the performance of the Atellica IM assays for the detection of HBV infection.
Comparative evaluation of Elecsys, Atellica, and Alinity assays for measuring the anti-Hepatitis C virus (HCV) antibody
This document presents a comparative evaluation of Atellica IM, ELECSYS, and ALINITY HCV antibody assays, showing good overall agreement (>95%), lower quantitative correlation for ELECSYS versus Atellica IM and ALINITY, and higher diagnostic sensitivity and PPV for Atellica IM and ALINITY, suggesting a greater potential for earlier disease detection.
Evaluation of the Analytical Performance of the Hepatitis A Total Antibodies Assay on the Atellica CI Analyzer
Precision, method comparison, detection capability (LoB, LoD, LoQ) and lineraity studies for the HAVT assay were evaluated using the Atellica CI Analyzer.
Comparison of high-throughput fully automated immunoanalyzers for detecting hepatitis B virus infection
This article compares the performance of the Atellica IMm assays for the detection of HBV infection.
Evaluation of the Analytical Performance of the Anti-Hepatitis B Surface Antigen Assay on the Atellica CI Analyzer
Precision, method comparison, detection capability (LoB, LoD, LoQ), and linearity studies for the Atellica IM aHBs2 assay were evaluated using the Atellica CI Analyzer.
Independent Performance Evaluation Comparative evaluation of Elecsys, Atellica, and Alinity assays for measuring the anti-Hepatitis C virus (HCV) antibody
This report presents the performance of three assays used for the measurement of anti‑hepatitis C virus (HCV) antibodies.
(Release for Mexico, Ecuador, Bolivia, Colombia, Argentina, Chile, International, Paraguay, Peru, Uruguay)
Analytical Performance Evaluation of the HIV Antigen/Antibody ComboAssay on the Atellica CI Analyzer
Precision and method comparison studies for the Atellica IM CHIV assay were evaluated using the Atellica CI Analyzer.
Analytical Performance Evaluation of the Anti-Hepatitis B Surface Antigen assay on the Atellica CI Analyzer
Precision, method comparison, detection capability (LoB, LoD, LoQ) and lineraity studies for the aHBs2 assay were evaluated using the Atellica CI Analyzer.
Independent Performance Evaluation - Comparative Evaluations of Atellica, ARCHITECT, and COBAS Treponema-specific Antibody Assays
This document provides a summary of Park et al. (2016), which evaluated percent agreement across syphilis assays from multiple manufacturers.
Comparative Evaluations of Atellica and Treponema-Specific Antibody Assays
This document synthesizes findings from two studies (Park et al., 2016; Park et al., 2019) evaluating comparative sensitivity and specificity of syphilis assays across manufacturers.
Evaluation of the Analytical Performance of the Total Antibodies to Hepatitis B Core Antigen Assay on the Atellica CI Analyzer
Precision and method comparison studies for the Atellica IM HBcT2 assay were evaluated using the Atellica CI Analyzer.
Evaluation of the Analytical Performance of the HIV Antigen/Antibody Combo Assay on the Atellica CI Analyzer
Precision and method comparison studies for the Atellica IM CHIV assay were evaluated using the Atellica CI Analyzer.
: Chronic Kidney DiseaseContinuum and Markers
This White Paper reviews chronic kidney disease, including its causes, complications, and methods for assessing kidney function.
: ELF Test Revolutionizing Liver Health Assessment by Optimizing Care Pathway to Hepatology Clinics
This White Paper introduces a framework describing considerations for the use of the ELF Test in the assessment of liver fibrosis in MASLD.
: Analytical Performance Evaluation of the Anti‑Müllerian Hormone Assay on the Atellica CI Analyzer
Precision, method comparison, detection capability (LoB, LoD, LoQ) and lineraity studies for the AMH assay were evaluated using the Atellica CI Analyzer.
Assessing the Analytical Performance of the Anti‑Müllerian Hormone Assay on the Atellica CI Analyzer
Precision, method comparison, detection capability (LoB, LoD, LoQ), and linearity studies for the Atellica IM AMH assay were evaluated using the Atellica CI Analyzer.
: Atellica Solution Portfolio and Sustainability:
A study of water consumption, power consumption, and liquid waste output
This White Paper summarizes a study conducted by Siemens Healthineers quantifying water use, electricity consumption, and liquid waste output of Atellica Solution Portfolio.
: Quantitative Determination of Apixaban:
Method Comparison Studies between Different Assays and Platforms
This white paper presents the role of antiseizure medications in epilepsy care, highlighting improved tolerability of newer agents and the value of therapeutic drug monitoring.

Laboratory Insights

Stay ahead of evolving IVD regulations and industry changes, with practical guidance on their potential impact on laboratory operations, product claims, and test utilization.

Customer Insights

Discover how leading laboratories are putting best practices into action. These real-word examples highlight measurable impact across clinical, operational and organizational performance.

Medical Affairs

Explore in‑depth scientific insights on our dedicated Medical Affairs website for healthcare professionals.

The website linked managed by Siemens Healthineers Medical Affairs. The content is non-promotional in nature and intended for scientific and educational exchange only with healthcare professionals.

The products/features herein are not commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.